Tiziana is developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered through the nose. The goal is to modulate immune activity through mucosal immune pathways, stimulate regulatory T cells, and target neuroinflammation in serious neurological conditions.
That already puts TLSA in a fascinating lane.
But the latest data update is where this story gets spicy.
On May 19, 2026, Tiziana announced updated clinical data from its ongoing Expanded Access program evaluating intranasal foralumab
in 14 patients with non-active Secondary Progressive Multiple Sclerosis, also called na-SPMS.
The data were updated from March 2025 through March 2026, and the company reported that intranasal foralumab continued to be extremely well tolerated over extended treatment durations.
Most importantly, Tiziana reported no new safety signals identified.
That matters.
A lot.
Progressive neurological conditions are not quick battles. These are long, difficult disease areas where patients may require treatment over extended periods. So when a company is developing a non-invasive intranasal approach that aims to reduce neuroinflammation without broad systemic exposure, safety and tolerability become central to the entire story.
This is not just “cool science.” This is exactly where the field is looking for cleaner, smarter approaches.
And then came the clinical trend data.
Tiziana reported favorable trends in disability stabilization, measured by EDSS, along with meaningful improvements in fatigue, measured by MFIS.
Here is the number that jumps off the page:
64% of patients achieved a clinically meaningful improvement of at least 4 points on the MFIS fatigue scale.
That means 9 of 14 patients hit the meaningful fatigue improvement threshold.
For progressive MS, fatigue is not some small background symptom. It can heavily affect daily function, quality of life, and independence. So when nearly
two-thirds of treated patients in this update reached a meaningful fatigue improvement threshold, that is the kind of detail that deserves a big red circle.
The disability stabilization signal also stands out.
Tiziana’s update showed only one confirmed disability progression event in the foralumab Expanded Access cohort. The company compared the curve against reference arms from the Phase 3
HERCULES trial in non-relapsing SPMS.
Now, let’s keep this clean.
The company clearly stated that the Expanded Access data are not statistically significant because of the small sample size and uncontrolled design. These are trend analyses, not definitive conclusions.
That distinction matters.
But here is why the setup still feels so
compelling: early trend data can become very important when it supports a larger, controlled clinical strategy already in motion.
And TLSA is not sitting on one isolated update hoping the market notices.
The company has a broader neuroinflammation platform building across multiple major disease areas.
According to the company’s April 2026 neuro presentation, the intranasal foralumab pipeline
includes:
Non-active Secondary Progressive Multiple Sclerosis
Multiple System Atrophy
Mild Alzheimer’s disease
ALS
Non-active SPMS Expanded Access
Moderate Alzheimer’s Expanded Access
That is not a narrow science project. That is a clinical map.
The latest MS update is the headline signal right now. But the broader platform is what makes this story feel bigger than
one press release.
In non-active SPMS, the company’s Phase 2 study is expected to report topline data in 2H 2026. That gives this story a defined clinical window, which is exactly the type of timeline that can keep attention building.
And it is not just MS.
The Multiple System Atrophy program adds another serious layer.
Tiziana’s April 2026 presentation describes MSA as a rapidly progressive neurological disorder caused by degeneration or atrophy of nerve cells in multiple areas of the brain. The presentation also states that MSA is classified as an orphan disease by the FDA and that there are no FDA-approved treatments available.
That is a tough disease area with a major unmet need.
The company’s MSA
Phase 2a study began dosing in August 2025 and is designed to assess microglial activation and MSA clinical outcome measures.
Then the Lucid Capital Markets update added another eyebrow-raiser: initial PET imaging data from the first two treated MSA patients showed up to approximately 35% reduction in SUV and approximately 24% reduction in SUVR within affected brain regions after intranasal
foralumab treatment.
Early? Yes.
Interesting? Also yes. Very yes.
The Alzheimer’s program adds even more depth.
Tiziana’s April 2026 presentation says the company received a letter to proceed for an IND to conduct a Phase 2 study of intranasal foralumab in Alzheimer’s disease patients. It also states that the Phase 2 trial for early symptomatic Alzheimer’s disease
started in December 2025 and will assess microglial activation as part of combination therapy with recently approved therapies.
That same presentation also notes that an Expanded Access program granted by the FDA to treat moderate Alzheimer’s disease began dosing in December 2024.
And here is a credibility marker that should not get buried:
Tiziana was awarded a $4M grant from the National Institutes of Health, National Institute on Aging, to study anti-CD3 in Alzheimer’s disease.
That is not fluff. That is outside scientific support tied to a major neurodegenerative disease category.
The ALS program adds yet another piece.
The April 2026 presentation states that a Phase 2 ALS study is supported by The ALS
Association, with a grant awarded to study intranasal foralumab in ALS patients in a 20-patient, dose-ranging Phase 2 clinical trial. The presentation also notes that the ALS Phase 2 study was expected to start in 1H 2026 and assess microglial activation.
So step back for a second.
MS.
MSA.
Alzheimer’s.
ALS.
All orbiting the same core theme: neuroinflammation.
That is the big picture here.
Tiziana is not just pushing one condition. It is testing whether an intranasal anti-CD3 approach can help regulate immune activity across multiple severe neurological diseases where inflammation may play a key role.
And now the Street angle is getting hard to ignore.
Lucid Capital Markets raised its 12-month price target on TLSA from $8 to $9 following the latest update.
In that same note, TLSA was listed at $1.35, with the table showing 566.7% to target.
That means the raised target implies
well over 450% potential from the cited $1.35 level.
For a company with a listed market cap of $157.7M, cash and equivalents of $12.0M, total debt of $0.0, enterprise value of $145.7M, and float of 69.8M, that spread is the kind of disconnect that can start pulling serious attention.
Tiny
market cap.
Raised $9 target.
Over 450% implied potential from the cited level.
No new safety signals identified in the latest 14-patient update.
64% meaningful fatigue improvement.
Only one confirmed disability progression event.
Multiple neuroinflammation programs
moving at once.
That is not a sleepy little biotech update.
That is a “wait, why is this not on more screens?” setup.
Now, this still needs to be viewed correctly.
TLSA is a clinical-stage biotech. The Expanded Access data are small, exploratory, uncontrolled, and not statistically significant. The next controlled datasets matter. Timelines
can shift. Clinical outcomes are never guaranteed.
But that is exactly why the next chapter could be so important.
The company already has fresh trend data in na-SPMS. It has a Phase 2 study expected to report topline data in 2H 2026. It has an MSA study underway. It has Alzheimer’s work supported by a $4M NIH grant. It has ALS work supported by The ALS Association. And it has a raised analyst target pointing
dramatically higher from the cited level.
That combination does not show up every day.
This still looks under-followed relative to the size of the clinical map.
And sometimes, the biggest moves start when a story shifts from “interesting science” to “the market may need to re-check the math.”
TLSA may be entering that zone now.
The latest brain signal is louder.
The platform is broader.
The target just moved higher.
And the clinical calendar has real dates attached.
For a small Nasdaq biotech sitting far below a raised $9 analyst target, this is exactly the kind of tension that can turn quiet attention into a crowd fast.
Keep TLSA on your screen.
This one is starting to look a lot less quiet.
To your
success,
Max Masters
Co-founder, Market Tips Newsletter
